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The presentation will begin with a discussion of the rationale 
for the use of respiratory control techniques in breast cancer. 
Data pertaining to the dosimetric gains of breath-hold and 
gating techniques will be reviewed and the expected clinical 
gains will be modelled based on the Darby data (NEJM, 2013). 
The range of respiratory control options will be presented 
and the pros and cons of each technique discussed.  The UK 
HeartSpare Study will be reviewed as an example of how to 
use research to increase national use of heart-sparing breast 
radiotherapy techniques. The presentation will finish with a 
discussion of potential future applications of respiratory 
control techniques and how to integrate them with advanced 
radiotherapeutic approaches. 
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IMRT: should IMRT be the standard of care for adjuvant 
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The use of IMRT for many cancers has increased in recent 
years.  In general, IMRT has been shown to improve 
conformality of target volume coverage, with improved high 
dose sparing of organs at risk (OAR), however, at the cost of 
increased volumes of normal tissue receiving lower doses of 
radiation.  Improved treatment planning and delivery 
technology have greatly advanced the practice of IMRT over 
time. 
Among women with breast cancer, two distinct “types” of 
IMRT are used, in very different circumstances with fairly 
well-defined benefits and costs.  Tangential or field in field 
IMRT has been used to improve delivery of chest wall/breast 
radiotherapy.  Inverse planned multifield or arc IMRT has 
been used to improve delivery of chest wall/breast + nodal 
radiotherapy. 
Tangential or field in field IMRT, either inverse or forward 
planned, has been shown to increase the ability of 
radiotherapy departments to improve the quality of 
treatment planning and delivery of tangential breast 
radiotherapy, through more efficient planning processes, 
improved dose homogeneity in the breast, and increased 
automation, while possibly decreasing toxicity.  
Inverse planned multifield or arc IMRT has been shown to 
improve dose conformality, particularly to facilitate inclusion 
of more complex treatment volumes, e.g. chest wall + 
internal mammary nodes,  in the anatomic setting of 
significant OAR, such as the heart and lungs.  Literature 
suggests that this is typically at the cost of higher volumes of 
normal tissue receiving low doses, greater dose 
inhomogeneity, and greater resources required for treatment 
planning and delivery.   
This session will discuss the balance between the benefits 
and downsides of the use of both types of IMRT, review 
potential indications for both, and provide illustrative 
examples of clinical cases and treatment plans. 
 
 
Symposium: Advanced technology assessment: Quality 
management in an era of rapidly evolving radiotherapy 
technology  
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How can the radiation oncologist secure patient safety  
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Radiotherapy has a long history of examining the risks and 
documenting adverse events. Pro-active risk assessment and 
the reactive analyses of events should be used in parallel in 
order to provide optimal results for risks management. 
Different methods of risks assessment are available but a 
combination of methods is needed to perform a complete 
evaluation. The reactive (retrospective) analysis of events is 
directly related to the recording and the reporting of events. 
Detailed analyses should be reported through the local 
and/or external reporting system with the primarily purpose 
of more widely disseminating the experience learnt to other 
professionals. It is important to document all funding and 
corrective actions in order to prevent the re-occurrence of 
such events and especially, to share the experience learnt as 
a result of the event. Two levels of recommendations should 
be provided: recommendations to institutions that provide 
radiotherapy services whose primary responsibility is patient 
safety and secondly, to national authorities which focus on 
the needs for strong support at the national or original level 
to promote culture that value risks management and safety. 
In the area of new technologies, educational program and 
practice risk analyses should be favored for the development 
or update the national strategy on quality and risk 
management to promote a safety culture in radiotherapy. 
Clinical audits and regulator inspections are also considered 
to play many important roles in a national strategy. These 
actions are aiming to identify assessing and analyzing and 
understanding on risk issues in order to rich an optimal 
balance of risks benefits and costs. All the actors involved in 
radiotherapy process should be concerned by these 
approaches (physicians, physicists, nurses, radiation 
technologists and companies). The most relevant advice that 
might be recommended to radiation oncologists aiming to 
implement new technologies is to participate to trials 
including a relevant quality assurance program.  
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The professional radiotherapy (RT) team comprised of 
radiation oncologists, medical physicist and radiation 
therapist (RTT) work through an integrated process to plan 
and deliver RT to cancer patients. Each step requires quality 
control (QC) and quality assurance (QA) measures to prevent 
errors and to give high confidence that patients will receive 
the prescribed treatment correctly. Not unlike the other 
professionals, the RTT is involved in a number of QC and QA 
measures. However, RTTs often are the last security barrier 
that will prevent a near incident from becoming an incident 
as they are often the pivot point between the pre-treatment 
phase and the treatment phase of the RT process.  
With the recent advances in RT, including intensity-
modulated and image-guided RT, QA demands on RTTs have 
dramatically increased. While the individualisation of 
treatments, precise positioning verification processes and 
increased in IT complexity have optimized patient treatment 
parameters, they also have resulted in the need for 
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systematic RTT QA procedures. These measures are 
compulsory for patient safety and quality but also need to be 
balanced with available resources. RTTs, sensitized to this 
issue and due to their position in the RT process, are 
therefore good candidates to become quality managers (QM) 
in a RT department.  
Since 2010, the Belgian national cancer plan has allowed for 
the progressive introduction of quality management systems 
(QMS) within the licensed radiotherapy departments.  
Between 2010 and 2013, the departments have been funded 
in order to hire one FTE QM whose role is to implement a 
QMS in the department in order to improve the processes and 
patient safety within the RT departments. This includes the 
recording and analysis of near-incidents and incidents 
through the PRISMA-RT (Prevention and Recovery Information 
System for Monitoring and Analysis in RadioTherapy) program. 
A short survey carried out in 2014 demonstrated that 41% of 
the hired QMs had a RTT professional background. Although 
lacking some theoretical background, RTTs are well adapted 
for the QM role and, and along with the non-RTT QMs,  are 
successful in implementing QMS within their departments as 
demonstrated by the preliminary results of the national 
clinical auditing program carried out by the Federal College 
of Radiotherapy using the IAEA methodology (QUATRO[1] 
(Quality Assurance Team for Radiation Oncology)).  
Furthermore, all RT QMs have decided to come together to 
form an association known as QMRT.be (Belgian association of 
Quality Managers in RadioTherapy) whose aim is to integrate 
the procedural requirements of a QMS within the clinical 
reality of patient treatment by acting as support system for 
all RT QMs. Since then, this group has been implicated in 
various projects such as PRISMA-RT expert group and QUATRO 
audits.  
 [1] Comprehensive Audits of Radiotherapy Practice: a tool 
for Quality Improvement. IAEA, Vienna, 2007 
(http://www.iaea.org/books). 
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Healthcare is inclining in the western world with growing 
costs. In the Netherlands it is assumed for instance that cost 
may rise from 13% GDP (90 billion euro) towards 30% GDP in 
2030. At the same time the public, patients, governement 
and  insurance companies question the quality of healthcare. 
From that perspective providers are asked to deliver a broad 
and often changing set of quality indicators to the different 
stakeholders to be used in public for ranking, transparancy 
and choosing information. In the “slipstream” of asking 
different indicators, often different levels for quality are 
defined by the stakeholders.  Irrespective of the perspective 
of “the outside” this will not give a proper insight in quality 
of healthcare and is not the way to initiate improvements of 
healthcare. The latter being important while improvement 
always goes with cost reduction. Quality improvement being 
to only proper way to initiate cost efficacy in healthcare.  
From that perspective already 8 years ago the professional 
boards of medical specialists started “clinical registries”. 
Bottom up collecting clinical information with an online  
feedback and nationwide benchmark, so professionals could 
see whether they are underperfoming or not. During the 
years this proved to be a strong improvement tool in all fields 
were clinical registries were implemented.  Development, 
implementation and exploitation of these registries is 
serviced by the Dutch Institute for Clinical Auditing (DICA; 
www.clinicalaudit.nl) a non-profit organisation driven by 
medical professinals.  At this time more than 17 registries are 
serviced by DICA, using strict preconditions regarding privacy, 
ownership , transparancy, autonomy of professional 
organisations etc. At his time existing registries are 
multidisciplinary extended, results are combined with Patient 
Related Outcome Maesurment’s (PROM’s) and financial data. 
In this way improvement of care at affordable costs with 
satisfied patients comes in reach. The next step is to allign 
data sets to come to global comparisons. During the  session 
“Advanced technology assessment; Quality management in an 
era of rapidly evolving radiology technology” more details 
regarding background, preconditions, results and future 
perspectives will be presented.  
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A better understanding of tumour biology has led to the 
development of targeted therapies, in which a drug is 
designed to disrupt a specific biochemical pathway important 
for tumour cell survival or proliferation.  The introduction of 
these drugs into the clinic has shown that patients can vary 
widely in their responses.  Molecular imaging is likely to play 
an increasingly important role in predicting and detecting 
these responses and thus in guiding treatment in individual 
patients [1].  We have been developing methods for 
detecting the early responses of tumours to therapy, 
including metabolic imaging with hyperpolarized 13C-labelled 
substrates, which we have used both to detect treatment 
response and to investigate the tumour microenvironment 
(reviewed in [2-4]).  Exchange of hyperpolarized 13C label 
between lactate and pyruvate [5] and net flux of label 
between glucose and lactate [6] have been shown to 
decrease post-treatment and hyperpolarized [1,4-
13C]fumarate has been shown to detect subsequent cell 
necrosis [7,8].  Tumour pH can be imaged using 
hyperpolarized H13CO3¯ [9] and redox state can be 
determined by monitoring the oxidation and reduction of [1-
13C]ascorbate and [1-13C]dehydroascorbate respectively [10]. 
 More recently we have shown that we can follow, using 
hyperpolarized [1-13C]pyruvate, the progression of pancreatic 
precursor lesions, in a genetically engineered mouse model of 
the disease, which potentially could be used clinically to 
guide earlier intervention. 
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